Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Men or women, age 18 to 50 years (inclusive) without significant medical history, physical or clinical lab abnormalities (as per protocol defined ranges)~* Women of childbearing potential must have negative urine pregnancy test and must be willing to use adequate birth control for 2 months following vaccination and have additional pregnancy tests as indicated~* Vaccinees must live alone or have no more than two household contacts willing to sign informed consent and participate in the study~* Household contacts must be healthy (based on medical history) men or women aged 18-65 years (inclusive)~Exclusion Criteria:~* Healthcare workers who have direct contact with patients who are immunodeficient, are HIV-positive, have unstable medical condition or are under the age of 18~* Childcare workers who have direct contact with children who are 2 years of age or younger or those employed in the food service industry~* Resides with HHCs who are under the age of 18 or over the age of 65~* Has abnormal stool pattern defined as fewer than 3 stools per week or more than 2 stools per day in past 6 months~* Has known allergy to, or known medical condition that precludes the use of both tetracycline or ciprofloxacin~* Previously received a licensed or investigational cholera vaccine~* Has history of cholera or enterotoxigenic E. coli infection (natural infection or experimental challenge)~* Travel to a cholera-endemic area and experienced symptoms consistent with traveler's diarrhea in the previous 5 years~* Received or plans to receive any other licensed vaccines from 14 days prior to the study vaccination until Day 28~* Received or plans to receive antibiotics (other than protocol-specified) or chloroquine within 14 days prior to the study vaccination through to Day 28

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PXVX0200 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).